Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-28
DOI
10.3389/fonc.2020.01642
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- (2020) Antoine Italiano et al. LANCET ONCOLOGY
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma
- (2019) Weixin Xie et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis
- (2019) Dan Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy
- (2019) Zhichao Tian et al. MEDICINE
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling
- (2019) Qiang Zhou et al. JOURNAL OF DRUG TARGETING
- Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
- (2019) Ian Judson et al. LANCET ONCOLOGY
- Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo
- (2019) Po-Jung Pan et al. Journal of Clinical Medicine
- Therapeutic Targeting of the IGF Axis
- (2019) Eliot Osher et al. Cells
- Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signaling
- (2019) Zhi C. Tian et al. Journal of Orthopaedic Translation
- 1676PDPhase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma
- (2019) N Gaspar et al. ANNALS OF ONCOLOGY
- Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
- (2019) Francesco Facchinetti et al. CLINICAL CANCER RESEARCH
- Recent advance in the development of novel, selective and potent FGFR inhibitors
- (2019) Feng-Tao Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
- (2019) Christopher P Wilding et al. Expert Review of Anticancer Therapy
- A new screening tool for FGFR inhibitor treatment?
- (2019) Aung Naing LANCET ONCOLOGY
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
- (2019) Guohui Liu et al. BMC Pharmacology & Toxicology
- RET fusions in solid tumors
- (2019) Andrew Y. Li et al. CANCER TREATMENT REVIEWS
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
- (2018) Bingxin Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
- (2018) Baorang Zhu et al. CANCER BIOLOGY & THERAPY
- Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
- (2018) Lesley J. Scott DRUGS
- Future applications of FGF/FGFR inhibitors in cancer
- (2018) Gaia Cristina Ghedini et al. Expert Review of Anticancer Therapy
- GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance
- (2018) Mihwa Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Axl inhibitors as novel cancer therapeutic agents
- (2018) Yingying Shen et al. LIFE SCIENCES
- Advances in studies of tyrosine kinase inhibitors and their acquired resistance
- (2018) Qinlian Jiao et al. Molecular Cancer
- The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- LOXO-292 Reins In RET-Driven Tumors
- (2018) Cancer Discovery
- Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
- (2018) M. Fioramonti et al. Scientific Reports
- Pazopanib in relapsed osteosarcoma patients: report on 15 cases
- (2018) Alessandra Longhi et al. ACTA ONCOLOGICA
- The possible role of insulin-like growth factor-1 in osteosarcoma
- (2018) Yu-sheng Li et al. CURRENT PROBLEMS IN CANCER
- Lenvatinib
- (2018) Koichi Suyama et al. Cancer Control
- A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
- (2018) James I. Geller et al. CANCER
- Sorafenib: key lessons from over 10 years of experience
- (2018) Bernard Escudier et al. Expert Review of Anticancer Therapy
- Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review
- (2018) Sherif Raouf et al. Future Oncology
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2018) Giuseppe Lombardi et al. LANCET ONCOLOGY
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
- (2018) Lu Xie et al. ONCOLOGIST
- KIT as a therapeutic target for non-oncological diseases
- (2018) Asuncion Martinez-Anton et al. PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
- (2017) Ziad Hussein et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
- (2017) Fariba Navid et al. INTERNATIONAL JOURNAL OF CANCER
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis
- (2017) C.-H. Heldin et al. JOURNAL OF INTERNAL MEDICINE
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
- (2017) Heming Li et al. Molecular Cancer
- Me too-drugs with limited benefits — the tale of regorafenib for HCC
- (2017) Bishal Gyawali et al. Nature Reviews Clinical Oncology
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- Knockdown of AXL Receptor Tyrosine Kinase in Osteosarcoma Cells Leads to Decreased Proliferation and Increased Apoptosis
- (2017) Y. Zhang et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy
- (2016) Mihwa Kim et al. Autophagy
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
- (2016) Rafael Rosell et al. LANCET ONCOLOGY
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
- (2016) Neyssa M Marina et al. LANCET ONCOLOGY
- Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors
- (2016) Amparo Sanchez-Gastaldo et al. Targeted Oncology
- Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
- (2016) Maryam Abbaspour Babaei et al. Drug Design Development and Therapy
- Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
- (2016) Wen-Ya Zhou et al. Cancer Biology & Medicine
- Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
- (2015) Mathilde Penel-Page et al. BMC CANCER
- Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells
- (2015) Sayaka I. Yamaguchi et al. CANCER SCIENCE
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Axitinib: A Review in Advanced Renal Cell Carcinoma
- (2015) Gillian M. Keating DRUGS
- Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulateVEGFR2in breast cancer cells
- (2015) Neil T. Pfister et al. GENES & DEVELOPMENT
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1
- (2015) D Weekes et al. ONCOGENE
- The importance of Src signaling in sarcoma
- (2015) QUANCHI CHEN et al. Oncology Letters
- A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
- (2014) Subhajit Roy et al. Anti-Cancer Agents in Medicinal Chemistry
- Insulin-like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?
- (2014) Bartosz Chmielowski CANCER
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance
- (2014) Alberto S. Pappo et al. CANCER
- A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
- (2014) E. Gabriela Chiorean et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis
- (2014) Satoshi Takagi et al. CANCER SCIENCE
- Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
- (2014) I. Plaza-Menacho et al. CELLULAR SIGNALLING
- Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
- (2014) J. M. Drake et al. MOLECULAR AND CELLULAR BIOLOGY
- Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
- (2014) Bérengère Gobin et al. PLoS One
- Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
- (2014) M. Fernanda Amary et al. Cancer Medicine
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- RET inhibition: implications in cancer therapy
- (2013) Maria Grazia Borrello et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases
- (2013) Carl-Henrik Heldin Journal of Neuroimmune Pharmacology
- Regorafenib for metastatic colorectal cancer
- (2013) Thierry André et al. LANCET
- Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
- (2013) Brenda Weigel et al. PEDIATRIC BLOOD & CANCER
- A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma
- (2013) Ding Chen et al. TUMOR BIOLOGY
- Central Role of RET in Thyroid Cancer
- (2013) M. Santoro et al. Cold Spring Harbor Perspectives in Biology
- The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
- (2012) Wei-feng Mao et al. ACTA PHARMACOLOGICA SINICA
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
- (2012) Johan Lennartsson et al. PHYSIOLOGICAL REVIEWS
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
- (2012) A N Rettew et al. Oncogenesis
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Cell surface receptor expression patterns in osteosarcoma
- (2011) Sheref E. Hassan et al. CANCER
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
- (2011) N. Itoh et al. JOURNAL OF BIOCHEMISTRY
- Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma
- (2011) Yin-He Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Direct Sensing of Endothelial Oxidants by Vascular Endothelial Growth Factor Receptor-2 and c-Src
- (2011) Monica Lee et al. PLoS One
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
- (2010) Paul W. Manley et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
- (2010) Gang Niu et al. CURRENT DRUG TARGETS
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors
- (2010) Elizabeth Fox et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome
- (2010) Irene Sulzbacher et al. PATHOLOGY
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
- (2009) Ayesha Abdeen et al. CANCER
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
- (2009) Rashmi Chugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
- (2009) Ymera Pignochino et al. Molecular Cancer
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Pediatric hematology oncology in Brazil
- (2009) Beatriz de Camargo et al. PEDIATRIC BLOOD & CANCER
- Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
- (2008) K.-G. Schmidt et al. Current Neuropharmacology
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started